Tezepelumab did not significantly decrease moderate or severe COPD exacerbations compared with placebo, the COURSE trial found.

Elevated CAR has been associated with adverse outcomes in many conditions, including cancer, sepsis, COVID-19, and cardiovascular diseases. A higher C-reactive protein to albumin ratio (CAR) is ...

GSK plc GSK recently announced that EMA has accepted the regulatory filing seeking approval for its IL-5 inhibitor ...

Depemokimab is a follow-up to GSK's Nucala (mepolizumab), a once-monthly IL-5 inhibitor approved for severe asthma, CRSwNP, ...

Explore strategies for controlling COPD and improving health, with a focus on management and lifestyle changes.

China Medical System Holdings Limited (the "Company", together with its subsidiaries, the "Group" or "CMS") is pleased to announce that on 24 January ...

Authenticated data presented in the Respiratory Drugs market report is based on findings of extensive primary and secondary research ...

Certain Medicare plans typically cover at least part of the cost of inhalers for COPD. There are also several ways to further save on costs.

Objectives To establish, within people with COPD, (1) whether ICS reduced MACE rates (acute coronary syndrome (ACS), heart failure (HF), ischaemic strokes or cardiovascular-specific death) compared ...

The announcement that inhaled insulin will soon be available in India has understandably generated a lot of excitement and ...

MACE incidence in patients with COPD initiating triple therapy was 11.3/100/year vs 8.7/100/year in patients using LABA-ICS. In patients with chronic obstructive pulmonary disease (COPD), the first ...